



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C07J 1/00, A61K 31/565, C07J 21/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/31112</b> <b>(43) International Publication Date:</b> 2 June 2000 (02.06.00)
<b>(21) International Application Number:</b> PCT/EP99/09053 <b>(22) International Filing Date:</b> 18 November 1999 (18.11.99)  <b>(30) Priority Data:</b> 98203914.1      20 November 1998 (20.11.98)      EP  <b>(71) Applicant (for all designated States except US):</b> AKZO NOBEL N.V. [NL/NL]; Velperweg 76, NL-6824 BM Arnhem (NL).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> LOOZEN, Hubert, Jan, Jozef [NL/NL]; Meerhoek 602, NL-5403 AC Uden (NL). SCHOONEN, Wilhelmus, Gerardus, Eduardus, Joseph [NL/NL]; Parklaan 16, NL-5345 BV Oss (NL).  <b>(74) Agent:</b> KRAAK, H.; P.O. Box 20, NL-5340 BH Oss (NL).		<b>(81) Designated States:</b> AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> ESTROGENIC ESTRA-1,3,5(10)-TRIENES WITH DIFFERENTIAL EFFECTS ON THE ALPHA AND BETA ESTROGEN RECEPTORS, HAVING A LINEAR HYDROCARBON CHAIN OF FROM 5-9 CARBON ATOMS IN POSITION 11  <b>(57) Abstract</b> <p>Disclosed is a novel class of steroid compounds based on estradiol, and carrying an 11<math>\beta</math>- substitution. Said substitution is a hydrocarbon group which may be linear or branched, provided that it comprises, as the longest chain on carbon atom no. 11 of the steroid skeleton, one single linear chain having a length of from 5 to 9 carbon atoms, wherein said chain may be saturated or unsaturated. The resulting compounds have a desirable mixed agonist/antagonist profile for estrogen receptor <math>\alpha</math> and estrogen receptor <math>\beta</math>.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## ESTROGENIC ESTRA-1,3,5(10)-TRIENES WITH DIFFERENTIAL EFFECTS ON THE ALPHA AND BETA ESTROGEN RECEPTORS, HAVING A LINEAR HYDROCARBON CHAIN OF FROM 5-9 CARBON ATOMS IN POSITION 11

5 The invention is in the field of estrogenic compounds of the type based on the molecular structure of estradiol. I.e., compounds having a steroidal skeleton the A-ring of which is aromatic, and having a free or capped hydroxyl group at carbon atom No. 3 and at either of carbon atoms Nos. 16 or 17. Estrogenic compounds have a generally recognised utility in the treatment of estrogen-deficiency related disorders, such as menopausal complaints, osteoporosis, and in contraception.

10


More precisely, the invention pertains to  $11\beta$ -substituted estradiol derivatives. Such  $11\beta$ -substituted estradiol derivatives are known from, *inter alia*, Napolitano et al. in J.Med.Chem. 1995, 38, 2774-2779. From this paper, it can be learned that placing a substituent at the  $11\beta$ -position may improve the binding affinity for the estrogen  
15 receptor, provided that said substituent is not too large. E.g., with an ethinyl group at  $C_{11}$ , the binding increases, whereas with the next higher homolog, 1-propinyl, it is reported that the binding affinity undergoes a marked drop.

The state of the art in the field of estrogen receptor affinity discriminates between two  
20 estrogen receptors, denoted  $ER\alpha$  and  $ER\beta$ , see Mosselman et al., FEBS Letters 392 (1996) 49-53 as well as EP -A- 0 798 378. Since these receptors have a different distribution in human tissue, the finding of compounds which possess a selective affinity for either of the two is an important technical progress, making it possible to provide a more selective treatment of estrogen-deficiency related disorders, with a  
25 lower burden of estrogen-related side-effects.

The present invention is based on the unexpected finding that, despite the above teaching, certain  $11\beta$ -substituted estradiol derivatives that deviate from those reported by Napolitano et al. possess a surprisingly higher estrogen receptor-affinity.  
30 Moreover, the present invention pertains to such  $11\beta$ -substituted estradiol derivatives

as have a selective affinity for both the estrogen receptors  $ER\alpha$  and  $ER\beta$ . By way of preference, the present invention pertains to such  $11\beta$ -estradiol derivatives as have a specific selective affinity in that these are agonists for  $ER\alpha$  and antagonists for  $ER\beta$ .

- 5 To this end, the invention resides in steroid compounds which satisfy the following structural formula I:



formula I

wherein:

- 10 one of X and Y is OH, the other being H;  
 $R_3$  is H, COR', with R' being alkyl\* or aryl;  
 $R_7$ ,  $R_{16}$ , and  $R_{17}$  each independently are H, alkyl\*, cycloalkyl\*, alkenyl\*, alkynyl\*,  
 aryl;  
 $R_{11}$  is a hydrocarbon group which may be linear or branched, provided that it  
 15 comprises one single linear chain having a length of from 5 to 9 carbon atoms as the  
 longest chain on carbon atom no. 11 of the steroid skeleton, wherein said chain may  
 be saturated or unsaturated;

- It should be noted that carbon chain length of the groups denoted with an asterisk (\*)  
 20 is not particularly critical, but will generally be up to eight for the aliphatic and  
 alicyclic groups, while aryl generally will be phenyl, pyridinyl, pyrimidyl, which  
 groups can have substitutions customary in the art, such as alkoxy, hydroxy, halogen,  
 nitro, cyano, and amino.

It should be noted that the exact structure of the estrogenic steroid skeleton is not critical as long as the regular requirements of an aromatic A-ring and hydroxyl groups on C<sub>3</sub> and C<sub>17</sub> or C<sub>16</sub> have been satisfied.

- 5 The present invention is directed to the 11 $\beta$ -substitution of such a steroid skeleton. It is the nature of the 11 $\beta$  substitution which has been found to lead to the unexpected effect on estrogen receptor affinity.

10 The mixed estrogen-receptor profile of the compounds according to the present invention, makes them suitable as improved estrogens, in the sense that they can be used in estrogen-related disorders, such as menopausal complaints and osteoporosis, and in contraception, and further may also be suitable in the treatment or prevention of Alzheimer's disease, breast tumor, benign prostate hypertrophy, and cardiovascular disorders. The preferred compounds of the invention, which have a marked ER $\alpha$   
15 agonistic and ER $\beta$  antagonistic profile, are particularly suitable in the treatment and prevention of estrogen-deficiency related disorders under diminished estrogen-related side-effects. The strongly ER $\beta$  antagonistic compounds of the invention can also have a utility in the treatment and prevention of endometriosis and other estrogen-related disorders.

20


As indicated above, the 11 $\beta$ -substituent is a hydrocarbon group comprising a single linear chain having a length of from 5 to 9 carbon atoms. This means that either the main chain of the substituent has a length of from 5 to 9 carbon atoms and any branches have a shorter chain length, or a short group is directly attached to carbon  
25 no. 11 of the steroid skeleton as what would normally be regarded as the actual substituent, in which case a side-chain must be present in such a manner that the total number of carbon atoms present in the longest chain attached to carbon atom no. 11 of the steroid skeleton is 5-9.

(68)

The number of carbon atoms in the single longest chain according to the invention preferably is lower than 9. More preferably, the number of carbon atoms is 5-7 with 5 or 6 being most preferred. It is further preferred that the  $11\beta$ -hydrocarbon chain is unbranched, and most preferably contains a double bond or a triple bond.

5

The  $11\beta$ -substituent, i.e.  $R_{11}$  in formula 1 preferably is selected from the following group of side-chain structures:



wherein X is  $\text{CH}_2$ , CH-alkyl, or  $\text{C}(\text{alkyl})_2$ ,  $R_1$  is H, alkyl,  $\text{C}_3$ - $\text{C}_7$  cycloalkyl, or together with X forms a  $\text{C}_3$ - $\text{C}_7$  ring system,  $R_2$  is H, alkyl, or  $\text{C}_3$ - $\text{C}_7$  cycloalkyl,  $R_3$  and  $R_4$  each independently are H, alkyl, or  $\text{C}_3$ - $\text{C}_7$  cycloalkyl optionally substituted with halogen or CN, n is an integer of from 0-9, m is an integer of from 1-5.

It is preferred that the further substituent groups denoted in the description of formula I are the following groups:

15 alkyl is (1-8C) alkyl, meaning a branched or unbranched alkyl group having 1-8 carbon atoms, for example methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, hexyl and octyl;

cycloalkyl is (3-6C)cycloalkyl meaning a mono- or bicycloalkyl group having 3-6 carbon atoms, e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl;

20 alkenyl is (2-8C)alkenyl, meaning a branched or unbranched alkenyl group having 2 to 8 carbon atoms, such as ethenyl, 2-butenyl, etc.; preferably alkenyl is (3-7C) alkenyl;

alkynyl is (2-8C) alkynyl, which means a branched or unbranched alkynyl group having 2-8 carbon atoms, such as ethynyl and propynyl; preferably alkynyl is (3-7C)

25 alkynyl;

The compounds of the invention may be produced by various methods known in the art of organic chemistry in general, and especially in the art of the chemistry of

steroids [see for example: Fried, J. and Edwards, J.A., "*Organic Reactions in Steroid Chemistry*", Volumes I and II, Van Nostrand Reinhold Company, New York, 1972]. The synthesis of the 11 $\beta$ -substituted estradiol derivatives of the invention does not present any special problems to the person of ordinary skill in the art, as is also  
5 evident from the examples given below. The compounds of the invention can also generally be synthesised analogously to the known 11 $\beta$ -substituted estradiol derivatives referred to above.

The present invention also relates to a pharmaceutical composition comprising the  
10 steroid compound according to the invention mixed with a pharmaceutically acceptable auxiliary, such as described in the standard reference Gennaro et al., Remington's Pharmaceutical Sciences, (18th ed., Mack publishing Company, 1990, see especially Part 8: Pharmaceutical Preparations and Their Manufacture.). The mixture of the steroid compounds according to the invention and the pharmaceutically  
15 acceptable auxiliary may be compressed into solid dosage units, such as pills, tablets, or be processed into capsules or suppositories. By means of pharmaceutically suitable liquids the compounds can also be applied as an injection preparation in the form of a solution, suspension, emulsion, or as a spray, e.g. nasal spray. For making dosage units, e.g. tablets, the use of conventional additives such as fillers, colorants.  
20 polymeric binders and the like is contemplated. In general any pharmaceutically acceptable additive which does not interfere with the function of the active compounds can be used. The steroid compounds of the invention may also be included in an implant, a vaginal ring, a patch, a gel, and any other preparation for sustained release.

25 Suitable carriers with which the compositions can be administered include lactose, starch, cellulose derivatives and the like, or mixtures thereof used in suitable amounts.

Furthermore, the invention relates to the use of the steroid compound according to the  
30 invention for the manufacture of a medicament in the treatment of estrogen-deficiency

related disorders such as peri- and/or post-menopausal complaints. Thus the invention also pertains to the medical indications of peri- and/or post-menopausal (climacteric) complaints and osteoporosis, i.e. a method of treatment in the field of HRT (hormone replacement therapy), comprising the administration to a patient, being a woman, of a compound as described hereinbefore (in a suitable pharmaceutical dosage form).

Further, the invention relates to the use of the steroid compound according to the invention in the manufacture of a medicament having contraceptive activity. Thus the invention also pertains to the medical indication of contraception, i.e. a method of contraception comprising the administration to a subject, being a woman or a female animal, of a progestogen and an estrogen as is customary in the field, wherein the estrogen is a compound as described hereinbefore (in a suitable pharmaceutical dosage form).

Finally the invention relates to the use of the steroid compound for the manufacture of a medicament having selective estrogenic activity, such a medicament being generally suitable in the area of HRT (hormone replacement therapy).

The dosage amounts of the present steroids will be of the normal order for estradiol derivatives, e.g. of the order of 0.01 to 10 mg per administration.

The invention is further illustrated hereinafter with reference to some unlimitative Examples and the corresponding formula schemes referred to.



## EXAMPLE 1

The synthesis of two compounds according to the invention, (10) and (11) in Scheme I is carried out as follows.

5

## 2

A mixture of 20 g of 11-butenylestrone 1, 12 ml of ethyleneglycol, 20 ml of triethylorthoformate and 0.5 g of p-toluenesulfonic acid was heated for 2 h. Then the mixture was cooled and poured into sat.aq.NaHCO<sub>3</sub>. The product was extracted into ethylacetate. After washing, drying and evaporation of the solvent, the crude product was treated with diisopropylether to afford 14 g of 2 as crystalline material; Mp 184-185. R<sub>f</sub> 0.58 (heptane/ethyl acetate 6/4).

10

## 3

To a solution of 0.5 g of 2 in 10 ml of THF was added 1 ml of dihydropyran, followed by 10 mg of p-toluenesulphonic acid. After stirring for 2 h the mixture was neutralized by addition of 0.5 g of NaHCO<sub>3</sub>. The mixture was stirred for 15 min. and then poured into water and extracted with ethylacetate. Upon passing the product through a short silica column, 600 mg of 3 was obtained as an oil; R<sub>f</sub> 0.75 (heptane/ethyl acetate 6/4).

20

## 4

To a solution of 600 mg of 3 in 10 ml of dry THF was added at 0°C 0.4 ml of 10M BH<sub>3</sub>.dimethylsulfide complex. After stirring for 1 h all starting material had been consumed. The mixture was carefully treated with 1.6 ml of 10% NaOH and 1,2 ml of 30%aq. H<sub>2</sub>O<sub>2</sub>. After stirring for 4 h the mixture was diluted with water and the product extracted into ethylacetate. Purification by column chromatography provided 470 mg of 4 as a viscous oil; R<sub>f</sub> 0.27 (heptane/ethyl acetate 6/4).

25

5

To a suspension of 17 g of sodium acetate, 35 g of silica gel, and 17 g of pyridiniumchlorochromate in 150 ml of methylene chloride was added a solution of 9.5 g of alcohol 4 in 20 ml of methylenechloride. After stirring the mixture for 1 h, the oxidation was completed and 200 ml of ether and 50 g of Celite was added. The mass was stirred for 15 min and then filtered over a celite path . The residue was concentrated and passed through a short silica gel column, to provide 9,1 g of 5;  $R_f$  0.55 (heptane/ethyl acetate 6/4)

10 6

To a suspension of 1.3 g of isopropyltriphenylphosphonium bromide in 10 ml of dry THF was added at -30°C 2.2 ml of a 1.5 M solution of butyllithium in hexane. The mixture was stirred for 15 min. At -30° and for 0.5 h at 0°. Then a solution of 0.47 g of aldehyde 5 in 2 ml of THF was added. After stirring for an additional 1 h at ambient temperature the reaction mixture was poured into water and extracted with ethyl acetate. Chromatography over silicagel, provided 450 mg of 6 as a colorless oil;  $R_f$  0.70 (heptane/ethyl acetate 7/3); starting material  $R_f$  0.46.

20 7

In a similar way as described above , the related cyclopropylidene derivative 6 was prepared from the aldehyde 5 and cyclopropyltriphenylphosphonium bromide .  $R_f$  0.65 (heptane/ethylacetate 7/3)

25 8

To a solution of 550 mg of 6 in 10 ml of acetone was added 2 ml of 2N HCl. The mixture was stirred for 1 hr. After neutralization with sat.aq.  $\text{NaHCO}_3$  the mixture was diluted with water and the product was extracted with ethyl acetate. The material thus obtained was triturated with 70% ethanol, to provide 360 mg of 8 as a white solid ; Mp 190-191 °C;  $R_f$  0.43 (heptane/ethyl acetate).

## 9

In a similar way as described for the related isopropylidene derivative 9 was prepared from the protected material 7 by treatment with 2N HCl; Mp 154-155 °C; R<sub>f</sub> 0.38 (heptane/ethyl acetate 7/3).

## 10

To a solution of 350 mg of 8 in a mixture of 3 ml of THF and 1 ml of abs.ethanol was added 60 mg of sodium borohydride. After stirring for 1 hr excess hydride was destroyed by addition of acetone and after stirring for an additional ½ hr the mixture was diluted with water and the product extracted with ethyl acetate. The product thus obtained was triturated with 60% ethanol, to provide 280 mg of 10; Mp 205-207°C.

## 11

In an analogous way as described above, reduction of 9 with sodium borohydride afforded the required estradiol derivative 11; Mp 178-179°C.

## EXAMPLE II

20

The synthesis of two further compounds according to the invention, (18) and (21) in Scheme II is carried out as follows.

## 12

To a solution of 1 g of 3 in 20 ml of dioxane was added 2.8 ml of 2% OsO<sub>4</sub> in t-butanol. After stirring this mixture for 10 min. 4 ml of water and 3.4 g of NaIO<sub>4</sub> were added. After stirring for 1 h the reaction was complete. The mixture was poured onto water, and extracted with ethyl acetate. After chromatography of the crude product 0.5 g of aldehyde 12 was isolated as an oil; R<sub>f</sub> 0.50 (heptane /ethyl acetate 6/4) 0.64 ; R<sub>f</sub> 3 : 0.75.

## 13

A solution of 6.9 g of triphenylphosphine was added at  $-70^{\circ}\text{C}$  to a solution of 4.38 g of tetrabromomethane in 30 ml of dichloromethane. The mixture which had turned  
5 orange was stirred additionally for 15 min. at  $0^{\circ}\text{C}$ , and then cooled again to  $-70^{\circ}\text{C}$ . A solution of 3 g of steroid 12 in 10 ml of methylene chloride was added and the mixture was stirred for another 1.5 h. The reaction was then poured onto sat.aq.  $\text{NaHCO}_3$  solution and extracted with dichloromethane. The product thus isolated was purified by chromatography to provide 1.39 g of 13; Mp  $163-164^{\circ}\text{C}$  (ethanol/water).

10

## 14

To a solution of 870 mg of 13 in 10 ml of acetone was added 1.6 ml of 1 N HCl. The mixture was stirred for 2 h. Then the reaction was neutralized by addition of  $\text{NaHCO}_3$ , followed by dilution with 50 ml of water. The product was extracted into ethyl  
15 acetate. After drying and concentration 0.70 g of 14 were obtained ;  $R_f$  0.60 (heptane/ethyl acetate 6/4).

## 15

To a solution of 3.7 g of 14 in 20 ml of methanol and 20 ml of THF was added 500  
20 mg of sodiumborohydride. After stirring for 1 h the mixture was poured into 250 ml of sat.aq. $\text{NH}_4\text{Cl}$  solution and extracted with ethyl acetate. After drying and concentration of the organic phase, the residue was crystallized from ether, to provide 2.7 g of 15 ; Mp  $142-144^{\circ}\text{C}$ ,  $R_f$  0.45 (heptane/ethyl acetate 6/4).

## 25 16

To a solution of 2 g of 15 in 40 ml of THF was added 6 ml of dihydropyran, followed by 45 mg of p-toluenesulphonic acid. After stirring for  $1\frac{1}{2}$  h the reaction mixture was poured into 200 ml of sat.aq.  $\text{NaHCO}_3$  solution , and the product was extracted into ethyl acetate, to provide 2,9 g of 16 as an oil;  $R_f$  0.78 (hexane/ethylacetate 6/4)

30

## 17

To a solution of 2.9 g of 16 in 50 ml of dry THF was added at -78 °C 6 ml of 1.6M BuLi (in hexane) solution. The mixture was stirred for 30 min. at this temperature . Then 1.4 ml of methyl iodide was added and the reaction was allowed to stir for 3 h at  
5 -15°C , followed by 3 h at room temperature. After pouring the mixture in 250 ml of water the product was extracted into ethyl acetate, and purification was performed by chromatography over silica gel, to provide 1.4 g of 17 as an oil;  $R_f$  0.38 (heptane/acetone 95/5);  $R_f$  0.71 (heptane/ethylacetate 6/4, starting material  $R_f$  0.78).

## 10 18

To a solution of 1.35 g of 17 in 30 ml of a 1/1 mixture of methanol/THF was added 100 mg of p-toluenesulfonic acid. After stirring for ½ h the mixture was poured into 100 ml of sat. aq. NaHCO<sub>3</sub> solution and the product was extracted into ethyl acetate. After chromatographic purification 510 mg of 18 was obtained as a white solid; Mp  
15 180-182°C,  $R_f$  0.35 (heptane/ethylacetate 6/4).

## 19

To a suspension of 2.2 g of cyclopropyltriphenylphosphonium bromide (previously  
20 dried over P<sub>2</sub>O<sub>5</sub> in vacuo at 80°C) in 30 ml of THF was added at -10°C 3.2 ml of a 1.6 M BuLi in hexane solution. After stirring for 1 hr at 0°C, a solution of 1.2 g of 12 in 5 ml of THF was added . The mixture was stirred for 1 h at room temperature and then poured into water. Extraction with ethylacetate, followed by chromatography , provided 0.93 g of 19 as an oil;  $R_f$  0.73 (heptane/ethyl acetate 7/3).

25

## 20

Deprotection of the ketal and tetrahydropyranyl ether was achieved by stirring 0.45 g of 19 in 10 ml of methanol in the presence of 50 mg of p-toluenesulphonic acid for 2 hr. The reaction mixture was poured into 5% aq NaHCO<sub>3</sub> solution and the product

was extracted with ethyl acetate. Chromatography provided 120 mg of pure **20**;  $R_f$  0.27 (heptane/ethyl acetate 7/3).

### 21

- 5 Reduction of the 17-keto group was achieved by treatment of a solution of 360 mg of **20** in a mixture of 5 ml of methanol and 5 ml of THF with 80 mg of sodium borohydride. After stirring for 2 h the mixture was poured into 30 ml of sat.aq.  $\text{NH}_4\text{Cl}$  solution and the product was extracted with ethyl acetate.. Chromatography, followed by trituration with heptane provided 230 mg of **21** as a white solid; Mp 178-179 °C.
- 10  $R_f$  0.44 (heptane/ethylacetate 6/4).

### EXAMPLE III

- 15 The compounds of Examples I and II, as well as several other compounds (synthesized in analogous manner) are tested for their estrogenic and anti-estrogenic activity.

Test medium: Intact recombinant CHO cells stably co-transfected with the rat  
20 oxytocin promoter and the luciferase reporter gene and either the human estrogen receptor  $\beta$  or the human estrogen receptor  $\alpha$ . Both cell lines have been produced within the Department of Biotechnology and Biochemistry (BBC) (N.V. Organon) and are known under the name CHO-ERRO 2B1-1E9 for CHO-ER $\alpha$  and CHO-ER $\beta$  RO LUC for CHO-ER $\beta$ .

25

- The estrogenic activity of compounds is determined in an in vitro bioassay (CHO-ER  
 $\alpha$ ) with recombinant Chinese hamster ovary (CHO) cells stably co-transfected with the human estrogen  $\alpha$  (hER $\alpha$ ), the rat oxytocin promoter (RO) and the luciferase  
reporter gene (LUC). The estrogenic activity (potency ratio) of a test compound to  
30 promote the transactivation of the enzyme luciferase mediated via the estrogen

receptor  $\alpha$  is compared with the standard estrogen Org 2317 (estradiol 1,3,5 (10)-estratriene-3,17 $\beta$ -diol). The estrogenic activity (potency ratio) of a test compound to promote the transactivation of the enzyme luciferase mediated via the estrogen receptor  $\beta$  is determined in the same fashion but using recombinant Chinese hamster  
5 ovary (CHO) cells stably co-transfected with the human estrogen  $\beta$  (hER $\beta$ ) (bioassay CHO-ER $\beta$ ).

The anti-estrogenic activity of compounds is determined in the same bioassays (CHO-ER $\alpha$  and CHO-ER $\beta$ ), but now the anti-ER $\alpha$  and anti-ER $\beta$  activity (potency ratio) of a test compound to inhibit the transactivation of the enzyme luciferase mediated via ER  
10  $\alpha$  or ER $\beta$  by Org 2317 (estradiol 1,3,5 (10)-estratriene-3,17 $\beta$ -diol) is measured.

The results are presented in the Table below. A rating of the compounds is given in which (-) means that it does not satisfy the ER affinity profile of the present invention, while (+) means a compound according to the invention, i.e. an agonist for ER $\alpha$  and  
15 an antagonist for ER $\beta$ .












(68)

Table A


Compound	ER- $\alpha$	ER- $\beta$	Rating
1	agonist	agonist	-
2	agonist	agonist	-
3	agonist	antagonist	+
4	agonist	agonist	-
5	agonist	antagonist	+
6	agonist	antagonist	+
7	agonist	agonist	-
8	agonist	antagonist	+
9	agonist	agonist	-
10	agonist	agonist	-
11	agonist	antagonist	+




Table B

 <p>(1)</p>	 <p>(7)</p>
 <p>(2)</p>	 <p>(8)</p>
 <p>(3)</p>	 <p>(9)</p>
 <p>(4)</p>	 <p>(10)</p>
 <p>(5)</p>	 <p>(11)</p>
 <p>(6)</p>	

Scheme I




Scheme II



## Claims:

1. A steroid compound satisfying the following structural formula:



formula I

wherein:


one of X and Y is OH, the other being H;

R<sub>3</sub> is H, COR', with R', being alkyl or aryl;

R<sub>7</sub>, R<sub>16</sub>, and R<sub>17</sub> each independently are H, alkyl, cycloalkyl, alkenyl, alkynyl, aryl;

- 10 R<sub>11</sub> is a hydrocarbon group which may be linear or branched, provided that it comprises one single linear chain having a length of from 5 to 9 carbon atoms as the longest chain on carbon atom no. 11 of the steroid skeleton, wherein said chain may be saturated or unsaturated.

- 15 2. A steroid compound according to claim 1, characterised in that R<sub>11</sub> is selected from the following group of side-chain structures:



- 20 wherein X is CH<sub>2</sub>, CH-alkyl, or C(alkyl)<sub>2</sub>, R<sub>1</sub> is H, alkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, or together with X forms a C<sub>3</sub>-C<sub>7</sub> ring system, R<sub>2</sub> is H, alkyl, or C<sub>3</sub>-C<sub>7</sub> cycloalkyl, R<sub>3</sub> and R<sub>4</sub> each independently are H, alkyl, or C<sub>3</sub>-C<sub>7</sub> cycloalkyl optionally substituted with halogen or CN, n is an integer of from 0-9, m is an integer of from 1-5.

3. A steroid compound according to claim 1, characterised in that the longest chain in  $R_{11}$  comprises 5-7 carbon atoms.
4. A steroid compound according to claim 3, characterised in that the longest chain  
5 in  $R_{11}$  comprises 5 carbon atoms.
5. A pharmaceutical composition comprising a steroid compound according to any one of the preceding claims, and pharmaceutically acceptable auxiliaries.
- 10 6. The use of a steroid compound according to any one of claims 1-4 for the manufacture of a medicine in the treatment of estrogen-deficiency dependent disorders.

## INTERNATIONAL SEARCH REPORT

Internat'l Application No

PCT/EP 99/09053

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07J1/00 A61K31/565 C07J21/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07J A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	C. LOBACCARO ET AL: "Steroidal Affinity Labels of the Estrogen Receptor. 3. Estradiol 11.beta.-n-Alkyl Derivatives Bearing a Terminal Electrophilic Group: Anti-estrogenic and Cytotoxic Properties" JOURNAL OF MEDICINAL CHEMISTRY., vol. 40, no. 14, 4 July 1997 (1997-07-04), pages 2217-2227, XP002100729 WASHINGTON US * page 2218, compound 5b * page 2219; table 1 page 2221; table 2 — -/-	1-6



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "a" document member of the same patent family

Date of the actual completion of the international search

30 March 2000

Date of mailing of the international search report

10/04/2000

Name and mailing address of the ISA

European Patent Office, P.B. 6818 Patentplan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Watchorn, P

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/09053

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>E. NAPOLITANO ET AL: "11.beta.-Substituted Estradiol Derivatives. 2. Potential Carbon-11-and Iodine-Labeled Probes for the Estrogen Receptor" JOURNAL OF MEDICINAL CHEMISTRY., vol. 38, no. 14, 7 July 1995 (1995-07-07), pages 2774-2779, XP002100730 WASHINGTON US cited in the application page 2776; table 1</p>	1-6
A	<p>DE 41 32 182 A (SCHERING AG) 25 March 1993 (1993-03-25) the whole document</p>	1-6
A	<p>WO 93 13123 A (ROUSSEL UCLAF) 8 July 1993 (1993-07-08) * the whole document, in particular, page 17, paragraph 3-4 *</p>	1-6

# INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/EP 99/09053

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
DE 4132182 A	25-03-1993	AT 146185 T CA 2119780 A DE 59207687 D DK 642529 T WO 9306124 A EP 0546591 A EP 0642529 A ES 2097924 T GR 3022692 T JP 7501792 T US 5502046 A	15-12-1996 01-04-1993 23-01-1997 02-06-1997 01-04-1993 16-06-1993 15-03-1995 16-04-1997 31-05-1997 23-02-1995 26-03-1996
WO 9313123 A	08-07-1993	FR 2685332 A AT 165365 T AU 666916 B AU 3357093 A CA 2124339 A CN 1075722 A,B DE 69225243 D DE 69225243 T EP 0623140 A ES 2115754 T FI 942944 A HU 68068 A IL 104105 A JP 7502281 T MX 9207421 A NZ 246624 A ZA 9209859 A	25-06-1993 15-05-1998 29-02-1996 28-07-1993 08-07-1993 01-09-1993 28-05-1998 29-10-1998 09-11-1994 01-07-1998 17-06-1994 29-05-1995 13-07-1997 09-03-1995 01-07-1993 21-12-1995 20-12-1993